This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


MAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.




Figure 1

MODULAR STRATEGY FOR DEVELOPING NON-PEPTIDE PROTEIN KINASE INHIBITORS



Optional side chains.

Figur 2 x-ray structur of (PKA):Mg₂ATP:pseudosubstrat inhibitor



In Closed Conformation

Figure 3

General Module M₁ Design Features For Binding To The Conserved Protein Kinase Catalytic Region






Figure 4
SUBSTRATE BEHAVIOR FOR BORONIC ACID PKA INHIBITORS 21 & 22



 $\label{eq:Figure 5} Figure \ 5$ $\label{eq:Figure 5} Binding \ interactions \ of src \ substrate$ $\ Ac-Ile-Tyr-Gly-Glu-Phe-NH_2 \ in \ model \ src \ active \ site.$

Figure 6

Design of naphthalene-based src inhibitor scaffold



src:peptide substrate complex

src:naphthalene-based non-peptide inhibitor binding mode

Figure 7 Design of isoquinoline and indole-based src inhibitor scaffolds

src:isoquinoline-based non-peptide inhibitor binding mode

src:indole-based non-peptide inhibitor binding mode

Figure 8

Figure 9





Figure 12




Figure 13

<u>77</u>


FIGURE 14



Ovarian Tumor N015 Sensitivity To Drugs: **Suspended Cell Culture**



Normal Human Fibroblasts Sensitivity To Src Inhibitors: Subconflu nt Cell Culture



KLM 2-31